Scenario | Mean incremental cost (95% CI) | Mean incremental QALY (95% CI) | ICERa | Probability of cost-effectiveness | Net monetary benefits | ||||
---|---|---|---|---|---|---|---|---|---|
BOOST programme vs. Best Practice Advice | BOOST programme vs. Best Practice Advice | P1 | P2 | P3 | NMB1 (95% CI) | NMB2 (95% CI) | NMB3(95% CI) | ||
Base case (Imputed, covariate adjusted, intention-to-treat) analyses | |||||||||
NHS and PSS perspective | 147.42 (− 419 to 714) | 0.020 (− 0.003 to 0.044) | 7211 | 0.673 | 0.745 | 0.832 | 145 (− 600.21 to 890.21) | 244 (− 570 to 1058.01) | 464 (− 531.90 to 1459.90) |
Sensitivity analysis | |||||||||
Societal perspective | 36 (− 470 to 541) | 0.021 (− 0.002 to 0.045) | 1745 | 0.788 | 0.836 | 0.886 | 208 (− 534.17 to 950.17) | 322 (− 521.72 to 1165.72) | 551 (− 522.92 to 1624.92) |
Complete case (non-imputed) attributable costs and QALYs, covariate adjusted | 182 (− 395 to 759) | 0.04 (0.009 to 0.070) | 4610 | 0.851 | 0.91 | 0.959 | 407 (− 374.37 to 1188.37) | 605 (− 287.15 to 1497.15) | 1000 (− 144.03 to 2144.03) |
Subgroup analyses | |||||||||
Age | |||||||||
65–74 years | − 6 (− 760 to 747) | 0.030 (− 0.003 to 0.063) | Dominant | 0.830 | 0.873 | 0.915 | 445 (− 501 to 1391) | 595 (− 459 to 1649) | 895 (− 413 to 2202) |
+ 75 years | 331 (− 529 to 1190) | 0.010 (− 0.024 to 0.045) | 32252 | 0.371 | 0.416 | 0.487 | − 183 (− 1243 to 877) | − 132 (− 1302 to 1038) | − 30 (− 1459 to 1399) |
Gender | |||||||||
Male | − 314 (− 1201 to 572) | 0.045 (0.009 to 0.080) | Dominant | 0.964 | 0.977 | 0.987 | 978 (− 103 to 2058) | 1201 (8 to 2393) | 1646 (188 to 3103) |
Female | 491 (− 245 to 1227) | 0.002 (− 0.030 to 0.035) | 201660 | 0.167 | 0.199 | 0.260 | − 467 (− 1398 to 464) | − 455 (− 1492 to 582) | − 431 (− 1716 to 854) |
Tilburg frailty indicator | |||||||||
Not Frail | 282.11 (− 539 to 1103) | 0.015 (− 0.020 to 0.050) | 18769 | 0.456 | 0.513 | 0.594 | − 58 (− 1075 to 960) | 17 (− 598 to 1044) | 168 (− 1231 to 1566) |
Frail | − 6 (− 809to 796) | 0.020 (− 0.014 to 0.053) | Dominant | 0.725 | 0.763 | 0.808 | 293.28 (− 700 to 1286) | 391 (− 2129 to 2209) | 587 (− 763 to 1937) |
ODI cut-off | |||||||||
ODI < = 22 | − 383 (− 1530 to 764) | 0.042 (− 0.004 to 0.088) | Dominant | 0.926 | 0.943 | 0.960 | 1004 (− 382 to 2390) | 1214 (− 313 to 2740) | 1634 (− 228 to 3496) |
ODI > 22 | 334 (− 327 to 994) | 0.018 (− 0.009 to 0.045) | 18677 | 0.437 | 0.521 | 0.640 | − 78 (− 902 to 746) | 11 (− 901 to 923) | 189 (− 930 to 1308) |
Fear avoidance belief score | |||||||||
0–14 | 346 (− 388 to 1079) | 0.019 (− 0.012 to 0.050) | 17877 | 0.452 | 0.532 | 0.645 | − 73 (− 983 to 837) | 23 (− 986 to 1033) | 216 (− 1028 to 1460) |
15 + | − 135 (− 1039 to 769) | 0.024 (− 0.014 to 0.061) | Dominant | 0.806 | 0.834 | 0.863 | 492 (− 628 to 1613) | 611 (− 631 to 1852) | 847 (− 679 to 2374) |
Hand grip strength | |||||||||
Men: < 30; Women: < 20 | 191 (− 738 to 1119) | 0.022 (− 0.015 to 0.059) | 8609 | 0.597 | 0.655 | 0.731 | 136 (− 998 to 1271) | 247 (− 1001 to 1496) | 468 (− 1051 to 1987) |
Men > = 30; Women > = 20 | 126 (− 628 to 881) | 0.020 (− 0.012 to 0.051) | 6404 | 0.642 | 0.698 | 0.768 | 164 (− 759 to 1087) | 263 (− 759to 1284) | 460 (− 797 to 1717) |